ERBB2 and breast cancer: Based on preclinical studies of breast cancer cell lines, HER2 amplification was found in a subset of patients with breast cancers and emerged as an important predictor of resistance to hormonal and chemotherapy regimens, time to relapse and overall survival (OS) (2).